Evaluation and Treatment of Myocardial Bridging by Clinical Phenotype Authors: Barry F. Uretsky, Srdjan B. Aleksandric, Srikanth Vallurupalli, Adib Chaus, Abdul Hakeem, James C. Blankenship, Yochai Birnbaum, Morton J. Kern Published: 2026 ABSTRACT Myocardial bridging (MB), most commonly involving the left anterior descending artery, is an intramyocardial segment of a coronary artery traditionally regarded as a benign anatomical variant. However, in a subset of patients, MB has been implicated in anginal syndromes, myocardial infarction, and even sudden cardiac death. Most cases are asymptomatic and identified incidentally on coronary computed tomography or invasive angiography. Controversy surrounds best practices for management of this entity. This review summarizes current evidence in adult patients with isolated MB on the mechanisms producing ischemia and adverse cardiac outcomes, the value of testing modalities to diagnose ischemia, and treatment strategies based on the patient’s symptoms and clinical presentation (phenotype). Introduction In patients with symptomatic myocardial bridging (MB), decision making involves determining if the MB is producing ischemia and associated symptoms.1, 2, 3 The current evidence base for MB treatment strategies remains incomplete. Any recommended pathway for evaluation and treatment must be considered a modest guide at best. A specifically tailored approach avoids unintended consequences. In the current era, an intramyocardial coronary segment is increasingly diagnosed by coronary computed tomography angiography (CCTA), often in asymptomatic patients or those with atypical symptoms. This situation results in diagnostic confusion for both patient and clinician. The purpose of this article is to review evidence (please see Appendix 1 in Supplemental Material for article selection process) supporting current diagnostic methods in evaluating the presence and mechanisms of ischemia in MB, describing different phenotypic MB presentations, and providing an approach to treatment. Diagnosis of MB Myocardial bridging is defined as a congenital coronary anomaly with dynamic stenosis seen on invasive coronary angiography characterized by systolic compression of an intramyocardial arterial segment and delayed early diastolic artery relaxation, leading to reduction of vessel luminal diameter in diastole.4,5 MB is usually observed in the mid- and/or distal left anterior descending artery (LAD; >90% of cases), and only rarely seen in the circumflex and right coronary arteries. Although MB by angiography is relatively uncommon (<5% in most series), an intramyocardial LAD vessel course without documentation of angiographic systolic constriction is much more frequently seen at autopsy or on CCTA6, 7, 8, 9, 10, 11, 12 (Table 1). In summarizing study results, this differentiation between angiographic MB and intramyocardial vessel course without knowledge of angiographic MB has been clarified wherever possible.Table 1Prevalence of intramyocardial coronary segmentsAuthor(s), yearNICS prevalence (%)ICS in LAD (%)Autopsy Geiringer, 19511510023100 Burnsides et al, 195610276587 Polacek and Kralove, 196117708660 Lee and Wu, 19721810858100 Penther et al, 19771918718100 Ferreira et al, 1991169056Unknown Baptista and DiDio, 199221825435 Ortale et al, 2001223756UnknownInvasive coronary angiography Noble et al, 19762852500.5100 Ishimori, 1980313131.6100 Greenspan et al, 19803716000.9100 Rossi et al, 19803811464.5100 Voss et al, 1980328482.5100 Kramer et al, 19822965812100 Irvin, 1982274657.5100 Angelini et al, 19833311004.5100 Somanath et al, 19893415001.1100 Gallet et al, 19913519201100 Diefenbach et al, 19943617803.5100 Juilliére et al, 19952574670.8100 Harikrishnan et al, 19993932000.6100 Soran et al, 2000265115100 Mookadam et al, 20092314,4161.693 Kim et al, 20092430013.3100Coronary CT angiography Kantarci et al, 2006436263.5100 Kawawa et al, 20074414815.891 Konen et al, 20074511830.594 Zeina et al, 2007463002691 Atar et al, 200747169768.5 Lubarsky et al, 20074824544100 De Rosa et al, 20084924218.721.3 Leschka et al, 20085015028.798 Johansen et al, 20081216732100 Ko et al, 2008514015.7100 Cademartiri et al, 2008535434.9100 La Grutta et al, 2009522773085 Kim et al, 20092430058100 Bayrak et al, 20091199022.562.6 Jodocy et al, 20105422123100 Lazoura et al, 20105587521100 Kim et al, 2010566076.484.2 Hwang et al, 201057127542100 Jeong et al, 20105812025100 Ma et al, 20139246213.664Please note this table cites some non-English articles as noted in reference list.CT, computed tomography; ICS, intramyocardial coronary segment; LAD, left anterior descending artery. Table 1Prevalence of intramyocardial coronary segmentsAuthor(s), yearNICS prevalence (%)ICS in LAD (%)Autopsy Geiringer, 19511510023100 Burnsides et al, 195610276587 Polacek and Kralove, 196117708660 Lee and Wu, 19721810858100 Penther et al, 19771918718100 Ferreira et al, 1991169056Unknown Baptista and DiDio, 199221825435 Ortale et al, 2001223756UnknownInvasive coronary angiography Noble et al, 19762852500.5100 Ishimori, 1980313131.6100 Greenspan et al, 19803716000.9100 Rossi et al, 19803811464.5100 Voss et al, 1980328482.5100 Kramer et al, 19822965812100 Irvin, 1982274657.5100 Angelini et al, 19833311004.5100 Somanath et al, 19893415001.1100 Gallet et al, 19913519201100 Diefenbach et al, 19943617803.5100 Juilliére et al, 19952574670.8100 Harikrishnan et al, 19993932000.6100 Soran et al, 2000265115100 Mookadam et al, 20092314,4161.693 Kim et al, 20092430013.3100Coronary CT angiography Kantarci et al, 2006436263.5100 Kawawa et al, 20074414815.891 Konen et al, 20074511830.594 Zeina et al, 2007463002691 Atar et al, 200747169768.5 Lubarsky et al, 20074824544100 De Rosa et al, 20084924218.721.3 Leschka et al, 20085015028.798 Johansen et al, 20081216732100 Ko et al, 2008514015.7100 Cademartiri et al, 2008535434.9100 La Grutta et al, 2009522773085 Kim et al, 20092430058100 Bayrak et al, 20091199022.562.6 Jodocy et al, 20105422123100 Lazoura et al, 20105587521100 Kim et al, 2010566076.484.2 Hwang et al, 201057127542100 Jeong et al, 20105812025100 Ma et al, 20139246213.664Please note this table cites some non-English articles as noted in reference list.CT, computed tomography; ICS, intramyocardial coronary segment; LAD, left anterior descending artery. Prevalence of intramyocardial coronary segments Please note this table cites some non-English articles as noted in reference list. CT, computed tomography; ICS, intramyocardial coronary segment; LAD, left anterior descending artery. An intramyocardial coronary course was first described anatomically in 1737 by Reyman13 and then by Black14 in 1805, while the first detailed post mortem analysis of this anomaly was documented by Geiringer.15 Autopsy incidence of MB has been reported from 15% to 85% in the LAD.16, 17, 18, 19, 20, 21, 22 In contrast, in vivo, LAD MB on invasive coronary angiography ranges from <0.6% to 13%.23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 Most LAD intramyocardial segments do not cause constriction angiographically, likely due to the location within the myocardium. The angiographic frequency may be augmented by using nitroglycerin28,39,40 or a β agonist41 (Figure 1, Supplemental Videos A1-A3 and B1-B3). Using intravascular ultrasound (IVUS), MB prevalence is ∼25%, with most MB being angiographically undetectable.42 Additionally, overlying tissue (called a halo) by IVUS has been utilized to diagnose an intramyocardial vessel course.42 MB incidence by CCTA has been reported in the 30% to 50% range.9,11,24,42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 58Figure 1Two invasive coronary angiographic examples in patient with isolated left anterior descending artery (LAD) myocardial bridging (MB, arrowhead). Angiographic sequences of same examples are shown in Supplemental images A1-A3 and B1-B3. (A) Angiogram of MB producing inducible myocardial ischemia on stress echocardiography and diastolic fractional flow reserve (dFFR). (A1-A3) MB compression (vs reference diameter) at end systole at baseline (A1) was 40%, after intracoronary nitroglycerin (NTG) was 59% (A2), and at peak (30-40 μg/kg/min) dobutamine (DOB) (A3) was 98%. (A4-A6) MB compression at end diastole at baseline (A4) was 29%, with intracoronary NTG (A5) was 41%, and with DOB was 48% (A6). (B) Angiogram of MB not producing inducible myocardial ischemia on stress echocardiography and dFFR of >0.76. B1-B3: MB compression (vs reference diameter) at end systole at baseline (B1) was 60%, after intracoronary NTG (B2) was 74%, and with DOB was 81% (B3). (B4-B6) MB compression at end diastole at baseline (B4) was 16%, after intracoronary NTG (B5) was 19%, and with DOB was 24% (B6), meaning that compression of the intramyocardial left anterior descending artery segment at end diastole was less impacted in this case without inducible ischemia. Two invasive coronary angiographic examples in patient with isolated left anterior descending artery (LAD) myocardial bridging (MB, arrowhead). Angiographic sequences of same examples are shown in Supplemental images A1-A3 and B1-B3. (A) Angiogram of MB producing inducible myocardial ischemia on stress echocardiography and diastolic fractional flow reserve (dFFR). (A1-A3) MB compression (vs reference diameter) at end systole at baseline (A1) was 40%, after intracoronary nitroglycerin (NTG) was 59% (A2), and at peak (30-40 μg/kg/min) dobutamine (DOB) (A3) was 98%. (A4-A6) MB compression at end diastole at baseline (A4) was 29%, with intracoronary NTG (A5) was 41%, and with DOB was 48% (A6). (B) Angiogram of MB not producing inducible myocardial ischemia on stress echocardiography and dFFR of >0.76. B1-B3: MB compression (vs reference diameter) at end systole at baseline (B1) was 60%, after intracoronary NTG (B2) was 74%, and with DOB was 81% (B3). (B4-B6) MB compression at end diastole at baseline (B4) was 16%, after intracoronary NTG (B5) was 19%, and with DOB was 24% (B6), meaning that compression of the intramyocardial left anterior descending artery segment at end diastole was less impacted in this case without inducible ischemia. Myocardial bridges are typically free of atherosclerosis.17,58, 59, 60, 61 Only rarely have atherosclerotic plaques been observed within an MB at autopsy, invasive coronary angiography, CCTA, and/or IVUS studies.62,63 However, atherosclerotic plaque is frequently observed proximal to the bridge. A proposed mechanism of plaque development is that endothelial coronary flow disturbances related to endothelial dysfunction, coupled with bidirectional (turbulent) blood flow and flow-generated low or oscillatory shear stress proximal to the bridge is a primary inciting factor for stimulating atherosclerosis.11,17,41,43,45,51,52,59, 60, 61,64, 65, 66, 67, 68, 69, 70, 71, 72, 73 Determining whether an MB is the cause of chest pain syndrome and/or myocardial infarction (MI) can be challenging, particularly because both these entities have been reported in the absence of a bridge.2 Thus, the issue remains whether the MB itself is the culprit for causing chest pain or is an innocent bystander and whether angiographic systolic compression is necessary to produce ischemia (in view of the relatively high incidence of intramyocardial vessels without angiographic systolic compression as noted earlier). Potential mechanisms of MB-induced ischemia Approximately 85% to 90% of coronary blood flow occurs during diastole. As such, it is unclear how an MB that obstructs blood flow during systole alone can cause ischemia. This is especially pertinent during a hyperemic response. Is the diastolic flow increase in the distal vasculature sufficient to compensate for the modest flow decrease during systole? There is a positive correlation between MB depth and systolic angiographic MB compression; however, the relationship between MB depth and angina or inducible ischemia is still unclear.7,24,74,75 At present, data are incomplete to state categorically that systolic MB compression of an intramyocardial segment is necessary to cause angina or whether an intramyocardial segment without systolic compression can also cause angina; this issue requires further study. Although MB is a congenital anomaly, it has been noted that clinical symptoms and objective signs of myocardial ischemia in patients often appear in the fourth or fifth decade of life.76, 77, 78, 79, 80 Why a previously asymptomatic patient becomes symptomatic or develops myocardial ischemia is incompletely understood but is likely that age-related left ventricle diastolic dysfunction, increases in ventricular fibrosis, and myocardial hypertrophy with concomitant increased oxygen demand may precipitate ischemia in some patients. Ischemic mechanisms of MB There are 3 major mechanisms that are postulated to explain ischemia: (1) functional and/or fixed diastolic coronary flow obstruction, (2) epicardial vasospasm, and (3) microvascular dysfunction, either functional (vasospasm) or fixed. The most supported explanation for exercise-induced ischemia is that blood flow is limited (in addition to systolic compression) in part, or all, of diastole, likely through incomplete relaxation during part or all of diastole and/or internal MB compression by encircling myocardium.5,61,75,81, 82, 83, 84 Studies have confirmed that anginal symptoms and/or objective signs of myocardial ischemia in patients with MB correlate well with the percent diameter stenosis and minimal luminal diameter at late diastole, but not during systole. Using quantitative coronary angiography, the percent diameter stenosis of the intramyocardial LAD at late diastole was an independent predictor of stress-induced myocardial ischemia.5 IVUS and/or quantitative angiographic studies have also found that systolic compression of the intramyocardial LAD segment persists during early diastole as a result of delayed relaxation, as well as a persistent diastolic diameter reduction during mid-to-late diastole.5,77,81, 82, 83, 84, 85 In these studies, the average MB diameter stenosis in mid-to-late diastole was between 29% and 41%, exceeding 50% in >10% of patients. These findings suggest that diastolic decompression of the intramyocardial LAD is delayed and followed by incomplete restoration of vessel diameter during mid-to-late diastole. Delayed early diastolic relaxation may be worsened by rapid atrial pacing, inotropic provocation with dobutamine (DOB) or exercise because of tachycardia and shortening of diastolic perfusion (filling) time, and increased strength of contraction.4,5,76, 77, 78, 79,82 Myocardial bridging demonstrates some unique aspects in coronary blood flow and pressure.61,78,81,83,86 The main coronary flow disturbances are characterized by (1) a unique diastolic coronary flow velocity profile (diastolic “finger-tip” phenomenon) at the MB site and distal to the MB; (2) retrograde systolic coronary flow; and (3) increased diastolic-to-systolic velocity ratio. The diastolic coronary flow velocity profile is characterized by a sudden coronary flow acceleration during early diastole, followed by a rapid deceleration during middiastole and a mid-to-late diastolic flow plateau. This diastolic finger-tip profile has also been observed noninvasively by transthoracic Doppler echocardiography and augmented during DOB provocation77 (Figure 2).Figure 2Diastolic flow pattern in the myocardial bridging segment.(A) Characteristic diastolic coronary flow velocity profile (diastolic finger-tip phenomenon [red arrows]) in the segment of left anterior descending artery (LAD) distal to the myocardial bridging (MB), obtained by transthoracic Doppler echocardiography during high-dose dobutamine provocation (30-40 μg/kg/min). This phenomenon is characterized by an abrupt coronary flow acceleration during early diastole, followed by a rapid deceleration during mid-diastole and mid-to-late diastolic flow plateau. (B) Schematic chart of interplay between percent diameter stenosis within the MB and diastolic coronary flow velocity within and distal to the MB. The major coronary flow disturbance in the LAD with MB occurs during early-to-mid diastole, when coronary flow and myocardial perfusion are at the highest level. Diastolic flow pattern in the myocardial bridging segment.(A) Characteristic diastolic coronary flow velocity profile (diastolic finger-tip phenomenon [red arrows]) in the segment of left anterior descending artery (LAD) distal to the myocardial bridging (MB), obtained by transthoracic Doppler echocardiography during high-dose dobutamine provocation (30-40 μg/kg/min). This phenomenon is characterized by an abrupt coronary flow acceleration during early diastole, followed by a rapid deceleration during mid-diastole and mid-to-late diastolic flow plateau. (B) Schematic chart of interplay between percent diameter stenosis within the MB and diastolic coronary flow velocity within and distal to the MB. The major coronary flow disturbance in the LAD with MB occurs during early-to-mid diastole, when coronary flow and myocardial perfusion are at the highest level. During early diastole in an epicardial LAD, ventricular relaxation results in rapid reduction in microcirculatory resistance and intracoronary pressure.86 There is an immediate increase in coronary perfusion pressure, followed by an immediate increase in diastolic coronary flow velocity. Gradual acceleration of coronary flow during early diastole is followed by a gradual decline until the beginning of systole. A similar coronary flow velocity profile exists in patients with obstructive coronary artery disease but with reduced hyperemic coronary flow response and reduced coronary flow reserve (CFR).87 In contrast, MB produces a very sharp increase in early diastolic coronary flow velocity in the intramyocardial LAD segment and distal vessel as a result of combined maximal coronary perfusion pressure and persistent diameter reduction, resulting in a steep pressure gradient across the MB (Figure 2).77,78,81, 82, 83,85 Lumen gain at middiastole rapidly reduces this pressure gradient and diastolic coronary flow velocity, which plateaus during mid-to-late diastole, when the intramyocardial LAD diameter is maximal.77,78,81, 82, 83,85 Thus, in MB, the major coronary flow disturbance occurs during early-to-mid diastole. Early diastolic myocardial perfusion is highest in the subepicardium, while subendocardial perfusion is delayed by 10 to 20 milliseconds and reaches only 45% of the maximal early diastolic subepicardial perfusion.80,86,88 As long as diastolic relaxation is completely preserved, early diastolic coronary flow and myocardial perfusion will remain intact. With significantly delayed early diastolic relaxation, coronary flow within and distal to the MB will be impaired and subendocardial perfusion below the ischemic threshold may occur; circumstances that decrease filling time and increase strength of myocardial contraction such as atrial pacing, DOB infusion, or exercise will exacerbate MB narrowing and ischemia.80,86,88 MB-associated ischemia may also be exacerbated by left ventricular diastolic dysfunction associated with aging and left ventricular hypertrophy, which directly affects early diastolic MB relaxation and diastolic perfusion time.79 Experimentally, coronary occlusion during systole and at least one-third of diastole will result in decreased blood flow and maldistribution away from the subendocardium.89 Ischemia limited to part of the septum across the LAD MB has been proposed as a cause of angina.90 On exercise echocardiography focal septal wall motion abnormality with apical sparing has been reported at peak stress.90 The authors proposed that there was focal septal ischemia due to a large increase in coronary flow velocity at early diastole through the narrowed intramyocardial LAD segment, causing a large pressure drop at the MB site with consequent abrupt decreased perfusion pressure in the septal branches, causing septal ischemia (septal steal phenomenon).80,86,91 It is unclear whether this phenomenon represents focal (septal) ischemia of clinical and prognostic significance, considering that noninvasive stress tests cannot demonstrate typical objective signs of moderate-to-severe ischemia. In addition to attributing ischemia to dynamic blood flow abnormalities in some patients, the bridge lumen is smaller than the proximal and distal vessel segments5,84,92 (Figure 3). In a study of 60 symptomatic patients with MB who underwent exercise stress echocardiography, the percent diameter stenosis at the MB site was significantly greater (38% ± 7% vs 27% ± 7%; P < .001), while minimal lumen diameter (1.54 ± 0.32 mm vs 1.95 ± 0.37 mm; P < .001) was significantly smaller angiographically at end diastole in the stress echocardiogram–positive patients compared with the stress echocardiogram–negative patients(38% ± 7% vs 27% ± 7%; P < .001; 1.54 ± 0.32 mm vs 1.95 ± 0.37 mm; P < .001, respectively).5 Maximal cross-sectional luminal area within the bridge on average was smaller than the vessel distal to the MB by IVUS84 and optical coherence tomography.92Figure 3This example shows the intramyocardial left anterior descending artery (LAD) segment at end diastole with a smaller diameter than the proximal and distal reference segments. (A) Angiogram at end diastole (proximal and distal myocardial bridging [MB] ends with white arrows). (B) Intravascular ultrasound (IVUS) of smallest site in MB: minimal lumen area (MLA), 4.4 mm2; minimal average luminal diameter (MLD), 2.3 mm at end diastole (B). (C) IVUS at end systole: MLA, 3.8 mm2; MLD, 2.0 mm at end systole. Note that, in diastole, the lumen of the intramyocardial LAD segment is circular and in systole ovoid. Red asterisk shows half-moon sign. (D) Vessel proximal to MB: MLA, 6.8 mm2; MLD, 3.0 mm. (E) Vessel distal to MB: MLA, 6.2 mm2; MLD, 2.8 mm. This example shows the intramyocardial left anterior descending artery (LAD) segment at end diastole with a smaller diameter than the proximal and distal reference segments. (A) Angiogram at end diastole (proximal and distal myocardial bridging [MB] ends with white arrows). (B) Intravascular ultrasound (IVUS) of smallest site in MB: minimal lumen area (MLA), 4.4 mm2; minimal average luminal diameter (MLD), 2.3 mm at end diastole (B). (C) IVUS at end systole: MLA, 3.8 mm2; MLD, 2.0 mm at end systole. Note that, in diastole, the lumen of the intramyocardial LAD segment is circular and in systole ovoid. Red asterisk shows half-moon sign. (D) Vessel proximal to MB: MLA, 6.8 mm2; MLD, 3.0 mm. (E) Vessel distal to MB: MLA, 6.2 mm2; MLD, 2.8 mm. Vasospasm has been implicated in ischemia in patients with MB. The intramyocardial LAD is generally free of atherosclerosis but appears to be more susceptible to epicardial vasospasm, typically limited to the MB segment but occasionally more diffuse.59,93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108 The frequency of induced vasospasm by intracoronary acetylcholine (ACh) has been high in multiple studies and higher than in a control group without MB (Table 2). What is less clear in most patients is the extent of the contribution of vasospasm to ischemia vs coronary flow changes from the bridge itself as described earlier.Table 2Development of epicardial coronary vasospasm with acetylcholine testingAuthors, yearNo of patientsClinical syndromeIncidence of vasospasmPMBNon-MBMBNon-MBBastiany et al, 20259366262Angina37.919.1<.01Sinha et al, 20241003062Typical angina54.029.0.12Allan et al, 202411130–CP37.0––Teragawa et al, 2022941547CP87.053.0.02Montone et al, 20219553257AP, n =161; MINOCA, n = 14179.054.9.001Pargaonkar et al, 202199154–Typical and atypical angina85.4––Sara et al, 2020982081261CP60.150.4.012Nam et al, 201897852–Typical and atypical angina59.1––Saito et al, 201796140252Not stated59.043.0.002Lee et al, 2015107139–Typical and atypical angina43.9––Xiang et al, 200910168148CP85.053.0<.001Kim et al, 2008102128231CP89.135.1.007Teragawa et al, 20031034173CP73.045.0.025AP, angina pectoris; CP, chest pain; MINOCA, myocardial infarction with nonobstructive coronary artery disease. Table 2Development of epicardial coronary vasospasm with acetylcholine testingAuthors, yearNo of patientsClinical syndromeIncidence of vasospasmPMBNon-MBMBNon-MBBastiany et al, 20259366262Angina37.919.1<.01Sinha et al, 20241003062Typical angina54.029.0.12Allan et al, 202411130–CP37.0––Teragawa et al, 2022941547CP87.053.0.02Montone et al, 20219553257AP, n =161; MINOCA, n = 14179.054.9.001Pargaonkar et al, 202199154–Typical and atypical angina85.4––Sara et al, 2020982081261CP60.150.4.012Nam et al, 201897852–Typical and atypical angina59.1––Saito et al, 201796140252Not stated59.043.0.002Lee et al, 2015107139–Typical and atypical angina43.9––Xiang et al, 200910168148CP85.053.0<.001Kim et al, 2008102128231CP89.135.1.007Teragawa et al, 20031034173CP73.045.0.025AP, angina pectoris; CP, chest pain; MINOCA, myocardial infarction with nonobstructive coronary artery disease. Development of epicardial coronary vasospasm with acetylcholine testing AP, angina pectoris; CP, chest pain; MINOCA, myocardial infarction with nonobstructive coronary artery disease. MB and microcirculatory abnormalities Patients with isolated MB may also have anginal pain and/or myocardial ischemia due to concomitant structural and/or functional abnormalities of the coronary microcirculation.3,109,110 Current guidelines distinguish 2 coronary microvascular dysfunction (CMD) endotypes, which may occur separately or synergistically: (1) structural microvascular remodeling characterized by impaired endothelium-independent vasodilation of intramyocardial arterioles as a consequence of lumen narrowing due to intimal and medial vascular smooth muscle hypertrophy, perivascular fibrosis, and capillary rarefaction; and (2) functional arteriolar dysregulation characterized by impaired endothelium-dependent vasodilation and paradoxical vasoconstriction of intramyocardial arterioles (microvascular spasm) in response to intracoronary ACh, that is, functional CMD or microvascular vasospasm.95,98, 99, 100,107,111,112 Several studies have shown a high prevalence of CMD in patients with MB (22%-60%). A recent study by Allan et al111 found that endothelium-independent CMD, microvascular spasm, and epicardial vasospasm occurred in 60%, 29%, and 37% of symptomatic patients with MB, respectively, with 77% having at least 1 abnormality. These findings suggest that MB may influence microvascular function remotely because endothelial dysfunction itself is characterized by altered bioavailability of vasoactive agents, especially nitric oxide synthase and endothelin-1.61,97,104, 105, 106,113 However, the exact relationship between MB and CMD requires further investigation. Although the MB itself is spared from atherosclerosis in most cases, the segment proximal to the MB may show some degree of atherosclerosis, albeit often relatively minor.69 It may summate with other mechanisms to produce ischemia distal to the bridge (Figure 4).Figure 4Potential mechanisms of angina and/or myocardial ischemia in patients with myocardial bridging (MB) and nonobstructive coronary artery disease. VSMC, vessel smooth muscle cell. Potential mechanisms of angina and/or myocardial ischemia in patients with myocardial bridging (MB) and nonobstructive coronary artery disease. VSMC, vessel smooth muscle cell. Tests to diagnose ischemia in patients with MB Exercise/DOB stress echocardiography Stress echocardiography using exercise or DOB is conceptually attractive for evaluating ischemia from fixed or dynamic MB obstruction. The test elicits 3 mechanisms for MB-related ischemia by increasing blood flow distal to the bridge, increasing MB constriction, and decreasing the diastolic period. Empiric data, however, have shown that in the majority of patients with MB with typical or atypical angina, stress echocardiography does not show a regional wall motion abnormality in the LAD territory. Aleksandric et al114 reported that exercise stress echocardiography was positive for myocardial ischemia in only 23 of 81 symptomatic patients (28%). In a CCTA study in which symptomatic patients with MB were compared with symptomatic patients with normal coronaries without MB and symptomatic patients with obstructive LAD disease and no MB, there was evidence of reduced CFR in over half the patients with MB, but only a small minority (18.8%) had stress-induced anteroseptal hypokinesis by stress echocardiography.115 In a study of 18 patients with MB with exertional chest pain, none had regional wall motion abnormality, which would be considered positive for ischemia but 16 of 18 demonstrated decreased and dyssynchronous radial strain in the anterior wall vs the posterior wall.116 In contrast, Kobayashi et al117 reported where 50 of 58 patients (86.2%) patients with MB and exertional chest pain showed septal wall motion abnormality (not further described) with exercise. The relatively low percentage of positive DOB stress echocardiography studies vs flow disturbance may be a matter of degree. Guerra et al115 has suggested that although flow diminishes with DOB, it may not decrease enough to cause wall regional motion abnormality. In their study, although regional wall motion abnormality was uncommon, it was more frequent in the patients with MB deep within the septum and associated with a lower CFR than in patients with more superficial bridges. Likewise, Aleksandric et al5,114 found that patients with regional wall motion abnormalities had lower diastolic fractional flow reserve (dFFR; see further) vs patients with MB without regional wall motion abnormalities and lower CFR with DOB. Whether an intramyocardial vessel course without systolic contraction can produce symptoms and its frequency and mechanism are incompletely understood currently. In a study of 11 patients with intramyocardial LAD on CCTA but no evidence of systolic constriction on angiography, neither longitudinal strain by echocardiography or a decrease in blood flow by positron emission tomography was observed, suggesting the importance of angiographic systolic contraction and the intramyocardial course in determining physiological significance of the MB.118 A potentially specific echocardiographic finding associated with MB has been described as midseptal buckling with apical sparing.90 This finding was associated with an abnormal DOB diastolic dFFR (see further) and doubling of invasively measured peak flow velocity. In view of these findings, the echocardiographic pattern was felt to show ischemia, possibly in the vascular territory of the septal perforators within the MB. This interpretation may be questioned insofar as an asymptomatic group of patients with MB has not to date been studied. In such an asymptomatic MB group, DOB dFFR may also have been low and flow velocity increased, which would then point to a lack of specificity. This finding as a manifestation of ischemia must be viewed with caution. Myocardial perfusion imaging Studies of symptomatic patients with MB have demonstrated reversible defects in the anteroapical regions by myocardial perfusion imaging in 25% to 50% of cases.119, 120, 121, 122 A few studies have shown positivity in almost all (>80%) patients123, 124, 125 or <10% in some other studies.26,37 The wide variation likely reflects selection or referral bias inherent to observational studies. Several studies have suggested that a threshold of 50% to 75% of systolic compression is required to induce myocardial perfusion defects.7,120,122,124 Treatment to remove the obstructive component, either by stenting or surgically (see further), has abolished the perfusion defect in most patients studied.125, 126, 127 These data support the hypothesis that a reversible anteroapical defect represents true ischemia. Invasive physiological testing Measuring a pressure gradient across a fixed stenosis during hyperemia (fractional flow reserve [FFR]) has been correlated in coronary artery patients with ischemia by noninvasive testing.128 The nonhyperemic index, instantaneous wave-free ratio (iFR), has, in turn, been shown to correlate relatively well with FFR. Both FFR and iFR have demonstrated efficacy in long-term follow-up in cohorts with coronary artery disease. The current thresholds defined for ischemia are 0.8 for FFR and 0.89 for iFR. Physiological testing has been proposed as a means of differentiating an MB causing ischemia vs an incidental bridge utilizing the same thresholds as for fixed stenoses.2,129 Further, it has been proposed that a physiological test limited to diastole should be more effective than whole cycle translesional pressure ratios because the dynamic nature of the MB and systolic constriction may cause a systolic pressure overshoot obscuring the coronary pressure loss during diastole. A specific modification of the standard FFR/iFR tests, combining the use of intravenous DOB with either a resting index, iFR (iFR DOB) or use of FFR limited to the diastolic period (dFFR DOB), has been proposed. There are studies providing evidence that iFR DOB or dFFR DOB can be used to evaluate ischemia distal to the MB. Escaned et al4 in a study of 12 patients with MB, chest pain, and an ischemic stress test or electrocardiogram (ECG) showed that dFFR DOB produced a larger MB pressure gradient than full-cycle FFR. However, only 5 of 12 patients with typical angina and a positive stress test developed an ischemic value (<0.8). In a study of 20 patients with chest pain and positive stress test, 17 (90%) showed significantly lower iFR DOB than those with full-cycle FFR DOB.76 Aleksandric et al5 studied prospectively 60 symptomatic patients with chest pain and >50% angiographic diameter reduction in the MB area. The value obtained by dFFR DOB was lower than that with full-cycle FFR.5 Thus, if one uses physiological testing and desires the lowest value, a diastolic measure with DOB seems preferable. There are some important caveats, however, regarding use of invasive physiological testing. The unproven assumption is that a low dFFR DOB or iFR DOB equates with ischemia causing angina analogous to what is seen in fixed obstructive disease. If the assumption is true, it is not clear why all the studied symptomatic patients with an ischemic stress test or other evidence of ischemia did not have an ischemic value by physiological testing. To date, very few asymptomatic patients with incidental MB have been systematically studied. It may be hypothesized that based on anatomic considerations, a lower value will also develop with DOB stimulation in asymptomatic patients with an incidental MB. As such, whether dFFR DOB or iFR DOB is reflective of ischemia causing angina or is nonspecific and present in asymptomatic patients is not known at present. If this test can be used for ischemia, it is fair to say that the ischemic threshold has yet to be adequately defined. In 1 study, the optimal threshold to detect ischemia by exercise-induced wall motion abnormality using dFFR DOB was 0.76, with sensitivity and specificity of ∼95%.5 This threshold was also found by Abe et al130 for fixed atherosclerotic stenoses using diastolic, rather than full-cycle, FFR. Current evidence is inadequate to recommend any physiologic index as a stand-alone definitive test of ischemia for MB. Until studies demonstrate that a physiological index is more frequently positive in patients with MB with other evidence of ischemia and not in the patient with asymptomatic MB, the use of any physiological measure as a sole determinant of ischemia does not seem to be warranted. A positive study may be considered adjunctive evidence of ischemia, which may be factored in decision-making in combination with the results of other studies. Should this physiological approach be confirmed, less invasive measures of flow, such as computed tomography FFR or coronary angiography FFR, may be used with greater confidence, particularly when a model incorporating changes in vessel structure is utilized. Testing for coronary vasospasm Myocardial bridging has been shown to be associated with increased frequency of epicardial and microvascular spasm. An intracoronary ACh provocation test is considered the gold standard for diagnosing coronary vasomotor disorders.2,3,131, 132, 133 To assess endothelial dysfunction, sequential intracoronary infusions of ACh with incrementally increasing doses are used.2,3,109 An ACh bolus of 20, 50, 100, and 200 μg with an interval of 2 to 3 minutes between each injection has been found to be effective. The ACh test is considered positive for epicardial coronary vasospasm and vasospastic angina if all of the following are present: (1) transient focal or diffuse epicardial coronary angiographic diameter reduction of ≥90% assessed by quantitative coronary angiography compared with that at baseline; (2) transient ischemic electrocardiographic changes (ST-elevation ≥ 0.1 mV, ST-depression ≥ 0.1 mV, or new appearance of negative U waves) in at least 2 contiguous leads; and (3) development of angina or anginal equivalent. Epicardial endothelial dysfunction (as opposed to frank vasospasm) is defined as any epicardial vasoconstriction of >0% but <90% after low-dose ACh provocation. Microvascular vasospasm, on the contrary, is characterized by angina and transient ischemic ECG changes but without epicardial vasoconstriction in response to ACh. Microvascular spasm may also be evaluated by measuring volumetric coronary blood flow using Doppler-tipped guide wire and quantitative coronary angiography during ACh provocation. An augmentation of coronary blood flow of <50% and CFR of ≤1.5 in response to ACh indicates the presence of microvascular vasospasm. However, an ACh test may not be able to detect microvascular vasospasm in the presence of severe epicardial vasospasm.109 In general, studies have demonstrated a high incidence of coronary vasomotor disorders in symptomatic patients (Table 2). It is not clear, however, whether spontaneous chest pain in an individual patient with MB is caused in part or totally by epicardial and/or microvascular vasospasm, as most episodes of spontaneous chest pain are not associated with marked ECG changes. CFR Myocardial bridging has been associated with an increased incidence of CMD as measured invasively by either coronary thermodilution or Doppler-based assessments.61,109 The reduced CFR below ischemic threshold accompanied by an increased vascular resistance (index of microcirculatory resistance of >25) in response to endothelium-independent vasodilatory agents such as adenosine or papaverine suggests structural inadequacy of the microvasculature.3,61,111,133 A reduced CFR below ischemic threshold with normal vascular resistance may be due to high resting coronary flow. CFR evaluation with ACh provocation to determine the possibility of microvascular spasm is useful in determining whether CMD may be due to dynamic vasoconstriction in the microvasculature. Positron emission tomography scanning may be useful in determining whether CFR is impaired.134 Therapeutic approach according to MB phenotype Therapeutic approach in patients with MB should be considered according to clinical phenotypes. Medical therapy using different antianginal medications is the first-line strategy for treatment of patients with MB (Central Illustration). However, therapy remains empiric because clinical studies evaluating efficacy and safety of these medications in MB management are lacking.Central IllustrationProposed evaluation and treatment approach of the myocardial bridging(MB) patient based on phenotype. The letter in parenthesis represents the phenotype described in text. Please refer to the text for description of each phenotype and proposed evaluation and treatment. ACh, acetylcholine; BB, β-blocker; CCB, calcium channel blocker; dx, diagnosis; CMD, coronary microvascular dysfunction; CP, chest pain; DSE, dobutamine stress echocardiography; IC, intracoronary; ICA, invasive coronary angiography; med Rx, medical therapy; MPI, myocardial perfusion imaging; Phys, physiologic; revasc, revascularization. Proposed evaluation and treatment approach of the myocardial bridging(MB) patient based on phenotype. The letter in parenthesis represents the phenotype described in text. Please refer to the text for description of each phenotype and proposed evaluation and treatment. ACh, acetylcholine; BB, β-blocker; CCB, calcium channel blocker; dx, diagnosis; CMD, coronary microvascular dysfunction; CP, chest pain; DSE, dobutamine stress echocardiography; IC, intracoronary; ICA, invasive coronary angiography; med Rx, medical therapy; MPI, myocardial perfusion imaging; Phys, physiologic; revasc, revascularization. Phenotype A: typical angina and positive stress test This presentation is the most straightforward to treat but unfortunately is likely the most infrequent presentation (Figure 5). In this scenario, the probability of ischemia caused by the MB is considered high. With predictability of angina onset, it is likely that MB stenosis, either functional, fixed or both, is present, limiting coronary blood flow as described earlier.Figure 5The need to treat myocardial bridging (MB) medically is relatively uncommon and. to treat with revascularization rare, relative to the frequency of the entity. This figure shows the incidence of an intramyocardial segment depending on the modality. At autopsy, the incidence of MB is 15% to 85%; by coronary computed tomography angiography (CCTA), 30% to 50%; and by coronary angiography, <1% to 15%. Symptomatic MB is a relatively small percentage of the MB population, most of whom can be treated with medication. It is only a very small fraction where revascularization is necessary to alleviate symptoms. CABG, coronary artery bypass surgery; CP, chest pain; IVUS, intravascular ultrasound; PCI, percutaneous coronary intervention. The need to treat myocardial bridging (MB) medically is relatively uncommon and. to treat with revascularization rare, relative to the frequency of the entity. This figure shows the incidence of an intramyocardial segment depending on the modality. At autopsy, the incidence of MB is 15% to 85%; by coronary computed tomography angiography (CCTA), 30% to 50%; and by coronary angiography, <1% to 15%. Symptomatic MB is a relatively small percentage of the MB population, most of whom can be treated with medication. It is only a very small fraction where revascularization is necessary to alleviate symptoms. CABG, coronary artery bypass surgery; CP, chest pain; IVUS, intravascular ultrasound; PCI, percutaneous coronary intervention. Medical therapy Medical therapy, specifically β-blockers and nondihydropyridine calcium channel blockers, has been universally recommended as the first step in treatment. Both drugs decrease inotropy; as such, systolic MB compression should decrease. Schwarz et al81 demonstrated that the intravenous β-blocker esmolol increased diastolic MB diameter and decreased flow velocity (vs no esmolol) during atrial pacing, confirming the theoretical value of decreasing contractile strength. Both medication classes decrease heart rate and thus increase diastolic filling time. If, in an individual patient, vasospasm is a component of decreased blood flow, the calcium channel blocker can alleviate vasospasm. Although selective β-blockers have been suggested to worsen vasospasm, current data have not described this phenomenon in patients with MB. It has been stated that nitrates should be used with caution—are to be avoided or frankly contraindicated.28,40,135,136 Concerns may be more theoretical than actual. Nitrates dilate the epicardial artery. If the MB is constrained from dilation and the rest of the vessel dilates, then the percent decrease in the bridge itself will be greater and measures of flow might worsen, for example, peak flow velocity. That should not affect the actual MB diameter and should not in principle worsen symptoms. In fact, in 1 of the first cases of myocardial unroofing, nitrates were initially useful in treating the patient’s chest pain.137 In a retrospective analysis in patients with MB with chest pain and vasospasm, the response rate of the combination of a calcium channel blocker and a nitrate (98%) was superior to calcium channel blocker alone (73%; P < .05).59 Other clinical studies have described nitrate use without adverse effects.25,56 There are, however, no large observational studies or placebo-controlled trials documenting a favorable effect of either β-blocker or calcium channel blocker on symptoms or findings of ischemia. The most convincing evidence that these drugs are effective derive from revascularization studies, where only a small percentage of symptomatic patients required revascularization, suggesting the value of medical therapy.138,139 For example, in a surgical study, the center identified 100 symptomatic patients, 81% of whom responded to medical therapy, leaving less <20% requiring revascularization.138 Novel agents for MB Other agents that reduce myocardial force or slow heart rate may alleviate symptoms in MB. Myosin-blocking agents, such as mavacamten, currently used or under investigation for the treatment of hypertrophic cardiomyopathy, may be useful but have not been studied.140 Ivabradine has been proposed as a therapeutic option but has also not been tested.135 In patients with predictable exercise-induced typical angina, the contribution of vasospasm in producing symptoms seems intuitively less likely. However, the high frequency of coronary vasospasm observed during ACh provocation testing underscores the potential significance of this mechanism in some anginal episodes (Table 2). The routine use of a coronary vasodilator, that is, calcium channel blocker, with this phenotype to proactively treat vasospasm seems reasonable even in the absence of formal testing for vasospasm. Revascularization of MB Revascularization, either surgically or percutaneously, should be limited to the very small group of patients who have severe angina despite maximal medical therapy (Figure 5). It is recommended that in general, strong evidence of ischemia be present, such as anteroapical ischemia on nuclear study or wall motion abnormality on stress echocardiography, although there may be occasional exceptions. Stenting Coronary stenting in patients with MB refractory to medical therapy remains controversial (Table 3).135,139,141,142 Several observational studies have demonstrated that a stent can be deployed relatively safely.139,142, 143, 144, 145, 146, 147 The acute complication of coronary perforation is likely higher than that in atherosclerotic lesions.147, 148, 149, 150, 151, 152, 153, 154 Long-term adverse events that may be higher than stenting atherosclerotic lesions include stent fracture and/or deformation (Table 3).146,155, 156, 157, 158, 159, 160, 161, 162, 163Table 3Stenting of myocardial bridgeAuthors, yearNStentFU (mo)Entry criteriaSuccess (%)Complication (type)TVR (%)Fracture (%)AP reliefa (%)Late AP (%)Ates et al, 202313912DES33CP refractory to MT + MPI921 (perforation)NANA1000Abdalwahab et al, 20231457DES20-72CP refractory to MT1000–NA1000Ernst et al, 201315515DES60CP, recent admission, +ETT (6), and +MPI (9)1001 (perforation)18.7–10018.7Schwarz et al, 200978,b13BMS60CP refractory to MT1000–9.11009.1Kunamneni et al, 2008163124 BMS and 8 DES12CP refractory to MT and +MPI1000–42–50Doshi et al, 20071474DESIHNA1001 (perforation)NANANANAWan and Wu, 20051384BMS26-46CP refractory to MT1000–5010050Kursaklioglu et al, 200414612BMS6CP refractory to MT and +MPI1000–6710041.6Haager et al, 200016211BMS4-5CP + MPI1000–4510036.3The table is limited to case series (>1 case). Single case reports are not included.AP, angina pectoris; BMS, bare metal stent; CP, chest pain; DES, drug-eluting stent; FU, follow-up; IH, in-hospital; MPI, myocardial perfusion imaging; MT, medical therapy; PCI, percutaneous coronary intervention; NA, not available/not applicable; TVR, target vessel revascularization.aAngina relief after the index intervention.bThe study described 24 patients, 11 of which were reported in the study by Haager et al,162 which included results of the study by Klues et al.83 Table 3Stenting of myocardial bridgeAuthors, yearNStentFU (mo)Entry criteriaSuccess (%)Complication (type)TVR (%)Fracture (%)AP reliefa (%)Late AP (%)Ates et al, 202313912DES33CP refractory to MT + MPI921 (perforation)NANA1000Abdalwahab et al, 20231457DES20-72CP refractory to MT1000–NA1000Ernst et al, 201315515DES60CP, recent admission, +ETT (6), and +MPI (9)1001 (perforation)18.7–10018.7Schwarz et al, 200978,b13BMS60CP refractory to MT1000–9.11009.1Kunamneni et al, 2008163124 BMS and 8 DES12CP refractory to MT and +MPI1000–42–50Doshi et al, 20071474DESIHNA1001 (perforation)NANANANAWan and Wu, 20051384BMS26-46CP refractory to MT1000–5010050Kursaklioglu et al, 200414612BMS6CP refractory to MT and +MPI1000–6710041.6Haager et al, 200016211BMS4-5CP + MPI1000–4510036.3The table is limited to case series (>1 case). Single case reports are not included.AP, angina pectoris; BMS, bare metal stent; CP, chest pain; DES, drug-eluting stent; FU, follow-up; IH, in-hospital; MPI, myocardial perfusion imaging; MT, medical therapy; PCI, percutaneous coronary intervention; NA, not available/not applicable; TVR, target vessel revascularization.aAngina relief after the index intervention.bThe study described 24 patients, 11 of which were reported in the study by Haager et al,162 which included results of the study by Klues et al.83 Stenting of myocardial bridge The table is limited to case series (>1 case). Single case reports are not included. AP, angina pectoris; BMS, bare metal stent; CP, chest pain; DES, drug-eluting stent; FU, follow-up; IH, in-hospital; MPI, myocardial perfusion imaging; MT, medical therapy; PCI, percutaneous coronary intervention; NA, not available/not applicable; TVR, target vessel revascularization. Angina relief after the index intervention. The study described 24 patients, 11 of which were reported in the study by Haager et al,162 which included results of the study by Klues et al.83 It cannot be resolved if the increased incidence of perforation is simply due to the protective effect of existing plaque. Histological and IVUS studies have shown that there may be deficient tissue within the MB, smaller diastolic diameter than proximal and distal to the MB, and relative stent overexpansion.84,92,150 An optical coherence tomography/IVUS study demonstrated that within the bridge the minimal lumen area was smaller and the wall thickness thinner than adjacent segments.91 These structural differences may account for the elevated perforation risk. In a study of bare metal stenting in 12 patients with MB,146 restenosis was 67%, compared with the control group with obstructive coronary disease of 28% (P = .037). However, more recent studies with drug-eluting stents suggest an incidence comparable with that in atherosclerotic lesions, albeit with small number of patients studied.139,145 The importance of intravascular imaging, particularly IVUS, for MB stenting has been emphasized.83 IVUS preprocedurally provides evidence of MB length and diameter, as well as proximal and distal reference diameters for proper stent sizing. After stent deployment, the extent of expansion and presence of any dissection at stent edge can be ascertained. Despite the concern for perforation as an acute complication, systematic IVUS use has not been studied. The fact that stenting can relieve ischemia has been demonstrated in case reports showing after successful stenting normalization of either a myocardial perfusion imaging or intravascular physiology study.83,146,163,164 It should also be noted that in retrospective analyses in patients with LAD stenting due to obstructive coronary disease proximal to the MB, restenosis was higher in the subgroup with the stent protruding into an MB vs stenting that did not include the MB.164, 165, 166, 167 In that regard, use of drug-eluting balloon for treating an atherosclerotic lesion proximal to the MB may be useful as a method to avoid perturbing the MB.168 In summary, MB stenting in drug-refractory patients has been reported in a limited number of patients. It is a relatively safe procedure, but with a higher incidence of perforation. In bare metal stent studies, the incidence of restenosis is unacceptably high, but drug-eluting stent studies suggest a restenosis rate comparable with those to atherosclerotic lesions. The addition of intracoronary imaging to improve outcomes and decrease complications is attractive, but outcome data with imaging are absent. Stenting may be a reasonable alternative for patients with persistent angina despite maximal medical therapy understanding the perforation risk. Further data are required to determine whether contemporary stenting is an effective strategy. Surgery Surgical intervention for MB by supra-arterial myotomy (unroofing) or bypass surgery in patients refractory to medical therapy has been utilized for >30 years (Tables 4 and 5).Table 4Surgical treatment of isolated myocardial bridge: myocardial unroofingAuthors, yearNFU time (mo)Entry criteriaSuccess rate (%)Acute complicationType of complicationCP improvement at FU (%)Late complication (%)Charaf et al, 20231711668CP refractory to MT1005RVE; 3 CABG68.80Ji et al, 20201743126CP refractory to MT10031 Dx injury; 1 RVE; 2 MI93.6TVR, 3.7Hemmati et al, 20201752531CP refractory to MT100133 RVE; 2 LADI; 4 CABGa; 4 reoperationsb630Ekeke et al, 20151772NACP with exercise10011 CABGNANABoyd et al, 2017141506.6CP refractory to MT1000–100d0Crespo et al, 20081722–CP100––100NAWu and Xu, 2007173831AP1000–1000Huang et al, 2007169335.3Not described1000–670Barylei et al, 200512710c51CP refractory to MT + MPI10021 RVE; 1 LAD injury/SVG; 2 conversion to CPB1000Rezayat et al, 20061782634CP refractory to MT + MPI (in 20)10054 RVE; 1 CABG88CABG, 3.8Iversen et al, 1992419NACP refractory to MT10032 RVE; 1 CABG100NAFaruqui et al, 1978170246 (patient 1)/9 (patient 2)Anterior STEMI and VF/CP during PSVT1001CABG; 2 of surgeon choice; 2 for deep MB100NAGrondin et al, 197717636CP and systolic milking1000–100NACABG, coronary artery bypass surgery; CP, chest pain; CPB, cardiopulmonary bypass; FU, follow-up; LAD, left anterior descending artery; LADI, LAD injury requiring repair; LIMA, left internal mammary artery; MI, myocardial infarction; MPI, myocardial perfusion imaging; MT, medical therapy; NA, not available; PSVT, paroxysmal supraventricular tachycardia; RVE, right ventricular entry during surgery requiring repair of connection; STEMI, ST segment–elevated MI; SVG, saphenous vein graft; TVR, target vessel revascularization; VF, ventricular fibrillation.aIn addition to unroofing, 4 patients had bypass surgery based on intraoperative findings.bReoperation was for 1 each of the following: bleeding, pericardial effusion with creation of pericardial window, chest tube insertion, and chest tube removal.cThree patients had coronary artery disease of other vessels with bypass at time of MB surgery and are not included.dData available in 38 of the 50 patients.Table 5Surgical treatment of isolated myocardial bridge: CABGAuthors, yearNType of graftFU time (mo)Entry criteriaSuccess rate (%)Acute complicationType of complicationCP improvement at FU (%)Late complication (%)Ghazy et al, 202118344LIMA64Failure of Med Rx1001Bleeding; 1 reoperation, CABG reoperation; 1 CVA; 1 VF, ICD93.2Death 4.5; 2.2Ji et al, 202017413aLIMA26.0CP refractory to MT1001Sternal infection; MI 7.661.5TVR, 15.4Bockeria et al, 201318039LIMA, n = 20/SVG, n = 1913.5/10.5CP refractory to MT + stress test1001Reoperation for bleeding80.0/89.00Sun et al, 201218113LIMA24CP refractory to MT and +MPI1000–1000Huang et al, 20071698LIMA35.3Not described1000–1000Wu and Xu, 20071733LIMA31AP1000–1000Pratt et al, 19991822LIMA10CP refractory to MT1000–1000CABG, coronary artery bypass surgery; CP, chest pain; CVA, cerebrovascular accident; FU, follow-up; ICD, implantable cardioverter-defibrillator; LIMA, left internal mammary artery; MI, myocardial infarction; MPI, myocardial perfusion imaging; MT, medical therapy; SVG, saphenous vein graft; TVR, target vessel revascularization; VF, ventricular fibrillation.aTen other patients had a high-grade LAD stenosis proximal to the MB. They are not included in this table. Table 4Surgical treatment of isolated myocardial bridge: myocardial unroofingAuthors, yearNFU time (mo)Entry criteriaSuccess rate (%)Acute complicationType of complicationCP improvement at FU (%)Late complication (%)Charaf et al, 20231711668CP refractory to MT1005RVE; 3 CABG68.80Ji et al, 20201743126CP refractory to MT10031 Dx injury; 1 RVE; 2 MI93.6TVR, 3.7Hemmati et al, 20201752531CP refractory to MT100133 RVE; 2 LADI; 4 CABGa; 4 reoperationsb630Ekeke et al, 20151772NACP with exercise10011 CABGNANABoyd et al, 2017141506.6CP refractory to MT1000–100d0Crespo et al, 20081722–CP100––100NAWu and Xu, 2007173831AP1000–1000Huang et al, 2007169335.3Not described1000–670Barylei et al, 200512710c51CP refractory to MT + MPI10021 RVE; 1 LAD injury/SVG; 2 conversion to CPB1000Rezayat et al, 20061782634CP refractory to MT + MPI (in 20)10054 RVE; 1 CABG88CABG, 3.8Iversen et al, 1992419NACP refractory to MT10032 RVE; 1 CABG100NAFaruqui et al, 1978170246 (patient 1)/9 (patient 2)Anterior STEMI and VF/CP during PSVT1001CABG; 2 of surgeon choice; 2 for deep MB100NAGrondin et al, 197717636CP and systolic milking1000–100NACABG, coronary artery bypass surgery; CP, chest pain; CPB, cardiopulmonary bypass; FU, follow-up; LAD, left anterior descending artery; LADI, LAD injury requiring repair; LIMA, left internal mammary artery; MI, myocardial infarction; MPI, myocardial perfusion imaging; MT, medical therapy; NA, not available; PSVT, paroxysmal supraventricular tachycardia; RVE, right ventricular entry during surgery requiring repair of connection; STEMI, ST segment–elevated MI; SVG, saphenous vein graft; TVR, target vessel revascularization; VF, ventricular fibrillation.aIn addition to unroofing, 4 patients had bypass surgery based on intraoperative findings.bReoperation was for 1 each of the following: bleeding, pericardial effusion with creation of pericardial window, chest tube insertion, and chest tube removal.cThree patients had coronary artery disease of other vessels with bypass at time of MB surgery and are not included.dData available in 38 of the 50 patients. Surgical treatment of isolated myocardial bridge: myocardial unroofing CABG, coronary artery bypass surgery; CP, chest pain; CPB, cardiopulmonary bypass; FU, follow-up; LAD, left anterior descending artery; LADI, LAD injury requiring repair; LIMA, left internal mammary artery; MI, myocardial infarction; MPI, myocardial perfusion imaging; MT, medical therapy; NA, not available; PSVT, paroxysmal supraventricular tachycardia; RVE, right ventricular entry during surgery requiring repair of connection; STEMI, ST segment–elevated MI; SVG, saphenous vein graft; TVR, target vessel revascularization; VF, ventricular fibrillation. In addition to unroofing, 4 patients had bypass surgery based on intraoperative findings. Reoperation was for 1 each of the following: bleeding, pericardial effusion with creation of pericardial window, chest tube insertion, and chest tube removal. Three patients had coronary artery disease of other vessels with bypass at time of MB surgery and are not included. Data available in 38 of the 50 patients. Table 5Surgical treatment of isolated myocardial bridge: CABGAuthors, yearNType of graftFU time (mo)Entry criteriaSuccess rate (%)Acute complicationType of complicationCP improvement at FU (%)Late complication (%)Ghazy et al, 202118344LIMA64Failure of Med Rx1001Bleeding; 1 reoperation, CABG reoperation; 1 CVA; 1 VF, ICD93.2Death 4.5; 2.2Ji et al, 202017413aLIMA26.0CP refractory to MT1001Sternal infection; MI 7.661.5TVR, 15.4Bockeria et al, 201318039LIMA, n = 20/SVG, n = 1913.5/10.5CP refractory to MT + stress test1001Reoperation for bleeding80.0/89.00Sun et al, 201218113LIMA24CP refractory to MT and +MPI1000–1000Huang et al, 20071698LIMA35.3Not described1000–1000Wu and Xu, 20071733LIMA31AP1000–1000Pratt et al, 19991822LIMA10CP refractory to MT1000–1000CABG, coronary artery bypass surgery; CP, chest pain; CVA, cerebrovascular accident; FU, follow-up; ICD, implantable cardioverter-defibrillator; LIMA, left internal mammary artery; MI, myocardial infarction; MPI, myocardial perfusion imaging; MT, medical therapy; SVG, saphenous vein graft; TVR, target vessel revascularization; VF, ventricular fibrillation.aTen other patients had a high-grade LAD stenosis proximal to the MB. They are not included in this table. Surgical treatment of isolated myocardial bridge: CABG CABG, coronary artery bypass surgery; CP, chest pain; CVA, cerebrovascular accident; FU, follow-up; ICD, implantable cardioverter-defibrillator; LIMA, left internal mammary artery; MI, myocardial infarction; MPI, myocardial perfusion imaging; MT, medical therapy; SVG, saphenous vein graft; TVR, target vessel revascularization; VF, ventricular fibrillation. Ten other patients had a high-grade LAD stenosis proximal to the MB. They are not included in this table. Supra-arterial myotomy (unroofing) Supra-arterial myotomy or myocardial unroofing in which myocardial fibers overlying the intramyocardial LAD are transected is the most frequently performed MB operation. The intramyocardial LAD course ranges from superficial to deep and near the right ventricle, which likely explains the complication of inadvertent right ventricular perforation during surgical dissection (Tables 4 and 5). Unroofing appears to be a technically successful procedure in most cases with an occasional need for bypass surgery during the unroofing procedure.67,169, 170, 171, 172, 173, 174, 175, 176, 177, 178 Chest pain relief occurs in most but not all patients. One report described atypical angina in about one-third of patients after unroofing despite the fact that CCTA demonstrated that the vessel was completely unroofed.171 This finding points out the difficulty in patient selection when the primary surgical indication is limited to the subjective complaint of chest pain without objective evidence of ischemia. It has been theorized that unroofing may be complicated by later fibrosis at the unroofing site, with the risk of recurrent obstruction.143 However, this complication has rarely been described141,174,175 (Tables 4 and 5). In a 1-year obligatory CCTA follow-up of 27 patients, recurrent vessel compression was observed in only 1 patient (3.7%).174 Although overall experience is limited, myocardial unroofing appears to be a relatively safe and effective treatment in alleviating chest pain not controlled with medication. Bypass surgery Coronary artery bypass graft surgery for an MB is counterintuitive (Table 5). Because of flow through the MB during diastole, continued patency of the bypass graft would seem significantly reduced.179 In clinical studies180, 181, 182, 183, 184 (Tables 4 and 5), all bypass procedures were performed successfully and all were described as producing immediate angina relief, albeit with a return of angina in some cases. In a study of 39 bypass patients with 1-year angiographic follow-up, the left internal mammary artery graft was patent in only 40% (8/20), compared with 84.2% of saphenous vein grafts.180 The authors attributed the paradoxical superior patency of saphenous vein grafts to the severity of the LAD lesion proximal to the graft. A similar result was reported by Ji et al174 in 23 MB bypass cases, which showed internal mammary graft patency rate in isolated MB cases was 30.8% compared with 100% internal mammary graft patency rate for patients with coronary stenosis proximal to the MB. Conversely, in another study, internal mammary grafts appeared to work well, with 7 grafts having routinely undergone CCTA at 1 year with all grafts being patent.181 There is a limited number of reported patients who have undergone bypass surgery, a lack of direct comparison with the unroofing procedure and high rate of internal mammary graft occlusion with bypass surgery. This suggests that unroofing, when technically feasible, may be a more favorable surgical option.174 Notably, bypass may be preferred for deep and extensive MB to avoid the risk of septal perforation into the right ventricle. Phenotype B: atypical angina pectoris and negative or equivocal stress test results Phenotype B is probably the most frequent phenotype encountered in clinical practice, other than the asymptomatic, incidentally discovered angiographic MB. For this phenotype, formal testing for ischemia, vasospasm, and microvascular function may clarify whether the MB is causing ischemia or blood flow limitation. Phenotype B may be caused by a variety of pathophysiological mechanisms alone or in combination as follows: (1) some degree of MB diastolic obstruction; (2) epicardial or microvascular vasospasm; (3) structural and/or functional CMD; and possibly (4) focal (septal) ischemia due to septal steal. Alternatively, there may be a coincident confluence of 2 entities, MB and chest pain, which are not causally related requiring a comprehensive invasive coronary functional testing (Central Illustration).2,132 Invasive coronary functional testing includes the following: (1) MB imaging with IVUS or optical coherence tomography; (2) physiological testing using dFFR or iFR during DOB provocation; (3) CFR and index of microcirculatory resistance during adenosine infusion using thermodilution and pressure wire technique, or CFR and hyperemic microcirculatory resistance during adenosine provocation using dual intracoronary Doppler and pressure wire technique; and (4) invasive vasoreactivity testing using ACh provocation test.2,132,133 Of note, invasive coronary functional testing should be performed after a washout period of 24 to 48 hours for smoking and drugs including β-blockers, calcium channel blockers, long-acting nitrates, trimetazidine and ranolazine, xanthine-containing foods, and beverages. It is recommended that invasive coronary functional testing be performed in the following order: (1) ACh testing first to evaluate epicardial and microvascular vasospasm, followed by intracoronary nitroglycerin; (2) adenosine infusion with CFR for assessing CMD; and (3) high-dose DOB infusion with dFFR or other nonhyperemic pressure ratios for evaluating the functional MB significance. Should empiric treatment with β and calcium channel blockers fail, invasive coronary functional testing may identify the presumed predominant mechanism of a patient without significant coronary disease or a patient with MB and MI without significant coronary disease, potentially leading to a more effective therapeutic approach. Further studies are required to determine the validity of this approach. If both noninvasive and invasive tests are normal in a patient with phenotype B, then an alternative diagnosis for the chest pain syndrome should be considered. Medical therapy for phenotype B is the same as for phenotype A with a negative inotrope, usually a β-blocker and calcium channel blocker. In phenotype B where vasospasm may be playing a more significant role than in phenotype A, vasodilators including a nondihydropyridine calcium channel blockers (and possibly nitrates) may be particularly useful. If medications are ineffective, then mechanical revascularization should considered, unless the clinician concludes that chest pain is due entirely to epicardial and/or microvascular vasospasm and/or CMD. Phenotype C: MB detected during workup of major adverse cardiac events Most adverse events, including MI, serious arrhythmias, and even sudden death, as described in case reports, have occurred unexpectedly, that is, not in a patient with a known symptomatic MB. Rather the MB is discovered while evaluating the cause of the adverse event. Myocardial infarction Myocardial infarction with nonobstructive coronary arteries (MINOCA) has been postulated to be related to transient thrombosis associated with subangiographic plaque disruption, coronary vasoconstriction, or spontaneous coronary artery dissection.184, 185, 186, 187 Any of these mechanisms could also be operative with MINOCA and MB. In a retrospective study of 141 patients with MINOCA, clinical predictors of MINOCA were the presence of an MB and a positive ACh test.95 During follow-up (median, 22 months), patients with MINOCA and MB had a higher adverse cardiac event rate than patients with MINOCA but without MB; patients with both MB and ACh-induced vasospasm had the highest adverse cardiac event rate. On the contrary, in a case-control study of MINOCA, the frequency of MB in the case controls and MINOCA was similar, suggesting that MB may have been a “fellow traveler” rather than the cause of the MI.188 In an autopsy study of 100 patients with MB with MI vs 100 patients without MI, the ratio of intimal to medial thickness, a marker of early atherosclerosis, was significantly increased in the MI group. This increased ratio, albeit with modest plaque, was felt to be a predisposing factor for development of MI,68 although the mechanism for MI remained uncertain. Because the number of cases of MI is small without any prospective data, treatment to prevent recurrent MI in patients discovered to have MB after the event is empiric at this time. It would be reasonable to utilize the same therapies as with phenotypes A and B. Serious arrhythmias/sudden death Serious arrhythmias and sudden death might be expected to occur in the setting of exercise, which combines increased sympathetic tone, presumed increased MB obstruction, and a decrease in diastolic filling time. However, a systematic review of the literature found only 35 cases of sudden death during exercise187 despite the relatively high MB prevalence in the general population. As with MB-associated MI, therapy must be considered empiric with the same drugs as in phenotypes A and B. Phenotype D: asymptomatic or incidentally detected MB Most patients with MB do not have symptoms, and the finding by invasive coronary angiography, IVUS, or CCTA is considered as incidental. It seems intuitive—but at present uncertain—if the same coronary hemodynamic changes occur in the asymptomatic as in the symptomatic patient, that is, diastolic finger-tip phenomenon, systolic retrograde coronary flow, high local systolic intracoronary pressure in the intramyocardial arterial segment, and increased diastolic systolic velocity ratio. Montone et al95 found that in patients with stable angina or MINOCA, only patients who developed epicardial vasospasm in response to intracoronary ACh had adverse events in follow-up. It was suggested that in asymptomatic patients, an ACh test be performed, and if positive, proactive treatment with vasodilators be considered.95 At present, limited empiric data do not support a proactive treatment approach based on the very low incidence of adverse cardiac events. Long-term follow-up There are relatively sparse data on long-term follow-up of patients with MB based on clinical phenotype.189, 190, 191, 192, 193, 194, 195 However, long term (≥1 year) follow-up appears to be excellent whatever the clinical presentation (Table 6).Table 6Long-term follow-up of patients with myocardial bridgeAuthors, yearNMB (n)Control (n)Entry criteriaFU (mo)MACE (%)Death (%)MI (%)A/SD (%)APMBControlMBControlMBControlMBControlMBControlAndreini et al, 2024190197197–CCTA and suspected CAD841.5–1.5a–0–0–11.2–Pargaonkar et al, 20201913131–Acute CP in E240–0–0–0–45.1–Nam et al, 201897812812–Atypical or typical AP60––0.36a–0.36–0–7.1–Dimitriu-Leen et al, 2017189947210737CCTA58.82.73.31.92.61.00.700––Rubinshtein et al, 20136434117217CP and CCTA737.76.06.05.51.70.500––Marcos-Alberca et al, 2011192743143CP and CCTA63.22.3003.22.300327Çiçek et al, 2011193118118–Systolic milking CA480–0–0–0–0–Sheu et al, 201119442589336CCTA21.90000000003.5Kim et al, 201056684308376CP and CA37.22.61.301.0a2.30.30.3016.47.2Schwarz et al, 200978157157–CP + abnormal ST or CFR (n = 99); no sx (n = 58)6015.2–0–0–0–15.2b–Ural et al, 20091955858–>70% MB CA370–0–0–0–18.6–Juilliére et al, 1995252828–CCTA12210.7–3a–0–0–––Kramer et al, 1993298181–Atypical or typical AP602.5–2.5a–0–0–0–In studies with control group, there were no significant differences.A/SD, arrhythmia/sudden death; AP, refractory/recurrent angina pectoris; CA, coronary angiography; CAD, coronary artery disease; CFR, coronary flow reserve; FU, follow-up; MACE, major adverse cardiovascular events (death, myocardial infarction, stroke, and serious arrhythmia); NA, not available/not applicable; ST, stress test; sx, symptoms.aNone of deaths were related to cardiac failure.bApproximately 15.2% of patients underwent stenting signifying severe or refractory symptoms. Table 6Long-term follow-up of patients with myocardial bridgeAuthors, yearNMB (n)Control (n)Entry criteriaFU (mo)MACE (%)Death (%)MI (%)A/SD (%)APMBControlMBControlMBControlMBControlMBControlAndreini et al, 2024190197197–CCTA and suspected CAD841.5–1.5a–0–0–11.2–Pargaonkar et al, 20201913131–Acute CP in E240–0–0–0–45.1–Nam et al, 201897812812–Atypical or typical AP60––0.36a–0.36–0–7.1–Dimitriu-Leen et al, 2017189947210737CCTA58.82.73.31.92.61.00.700––Rubinshtein et al, 20136434117217CP and CCTA737.76.06.05.51.70.500––Marcos-Alberca et al, 2011192743143CP and CCTA63.22.3003.22.300327Çiçek et al, 2011193118118–Systolic milking CA480–0–0–0–0–Sheu et al, 201119442589336CCTA21.90000000003.5Kim et al, 201056684308376CP and CA37.22.61.301.0a2.30.30.3016.47.2Schwarz et al, 200978157157–CP + abnormal ST or CFR (n = 99); no sx (n = 58)6015.2–0–0–0–15.2b–Ural et al, 20091955858–>70% MB CA370–0–0–0–18.6–Juilliére et al, 1995252828–CCTA12210.7–3a–0–0–––Kramer et al, 1993298181–Atypical or typical AP602.5–2.5a–0–0–0–In studies with control group, there were no significant differences.A/SD, arrhythmia/sudden death; AP, refractory/recurrent angina pectoris; CA, coronary angiography; CAD, coronary artery disease; CFR, coronary flow reserve; FU, follow-up; MACE, major adverse cardiovascular events (death, myocardial infarction, stroke, and serious arrhythmia); NA, not available/not applicable; ST, stress test; sx, symptoms.aNone of deaths were related to cardiac failure.bApproximately 15.2% of patients underwent stenting signifying severe or refractory symptoms. Long-term follow-up of patients with myocardial bridge In studies with control group, there were no significant differences. A/SD, arrhythmia/sudden death; AP, refractory/recurrent angina pectoris; CA, coronary angiography; CAD, coronary artery disease; CFR, coronary flow reserve; FU, follow-up; MACE, major adverse cardiovascular events (death, myocardial infarction, stroke, and serious arrhythmia); NA, not available/not applicable; ST, stress test; sx, symptoms. None of deaths were related to cardiac failure. Approximately 15.2% of patients underwent stenting signifying severe or refractory symptoms. Participation in competitive sports A 2025 American College of Cardiology/American Heart Association scientific statement considers MB a clinically insignificant finding that should not preclude an individual from competitive sports or other strenuous physical activity with the exception of individuals with symptoms and evidence of inducible ischemia. In this circumstance, active treatment and refraining from all competitive sports is recommended.196 Conclusions Evidence regarding diagnostic and treatment approaches in MB is limited by the lack of controlled trials and evaluation of invasive coronary functional testing of asymptomatic patients with MB. In patients with MB and typical angina and positive ischemia imaging test, ischemia from the MB has a high probability to be the basis for chest pain. That patient likely has a major element of vascular obstruction, either fixed from a somewhat narrowed MB or functionally from the persistent diastolic decrease in size and possibly a component of inappropriate vasoconstriction. Medical therapy with negative inotropic and chronotropic agents (β-blocker and calcium channel blocker) and antivasospastic drug (calcium channel blocker) is usually effective. When chest pain is refractory to medical therapy and the likelihood of ischemia is high, revascularization approaches should be considered (Central Illustration). In patients with atypical angina, the mechanism for the chest pain may be related to epicardial endothelial dysfunction, structural and/or functional CMD dysfunction, or epicardial diastolic MB coronary flow obstruction or a combination of these mechanisms. Medical therapy as described earlier may be helpful. If chest pain is refractory despite medical therapy, invasive coronary functional testing should be considered, including intravascular imaging, physiological testing (iFR or diastolic FFR), with DOB ACh provocation, and testing of microvascular competency to try to elucidate a mechanism for the chest pain. If all studies are normal, then an alternative explanation for the patient’s chest pain should be sought. If tests suggest flow limitations in the epicardial LAD, then revascularization approaches may be considered, understanding that symptom relief is less certain in this type of patient due to the atypicality of symptoms. In a rare patient with MB who presents with an MI, ventricular arrhythmia, or resuscitated sudden death and normal coronaries, the appropriate treatment is uncertain. Medical therapy to prevent vasospasm and decrease myocardial contractility, as used in the settings noted earlier, may be tried in this setting. For the asymptomatic patient, based on limited outcome data showing good prognosis, there does not appear to be a need for medical therapy. CRediT authorship contribution statement Barry F. Uretsky: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Srdjan B. Aleksandric: Writing – review & editing, Formal analysis, Conceptualization. Srikanth Vallurupalli: Writing – review & editing. Adib Chaus: Writing – review & editing. Abdul Hakeem: Writing – review & editing. James Blankenship: Writing – review & editing. Yochai Birnbaum: Writing – review & editing. Morton Kern: Writing – review & editing, Conceptualization. Peer review statement Section Editor Morton J. Kern had no involvement in the peer review of this article and have no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Editor-in-Chief Alexandra J. Lansky. Declaration of competing interest Morton J. Kern is a consultant for Opsens/Haemonetics, CathWorks, and Abbott. Barry F. Uretsky has received research support from Philips. The other authors report no relationships with industry or other disclosures related to this manuscript.